格林受体对药物作用进行编码的结构和功能
Yuki Shiimura1,2, Dohyun Im3, Ryosuke Tany4
1Division of Molecular Genetics, Institute of Life Science, Kurume University, Fukuoka, Japan. shiimura_yuuki@kurume-u.ac.jp.
Nature structural & molecular biology
|January 20, 2025
概括
格林受体药物阿纳莫雷林 (anamorelin) 显示出超激素活性. 结构洞察力揭示了不同的药物结构如何影响受体信号,并可以根据厌食症,肥胖症和糖尿病的遗传变异来个性化治疗.
科学领域:
- 药理学和结构生物学.
- 内分泌学和代谢性疾病.
背景情况:
- 格林林受体 (GHSR) 向药物显示出对厌食症,肥胖症和糖尿病的承诺.
- 开发有效的GHSR调节器受到复杂的药物标相互作用的阻碍.
研究的目的:
- 阐明阿纳莫雷林在 ghrelin 受体上的作用的结构基础.
- 为了比较阿纳莫雷林的机制与其他合成林受体配体.
- 探索结构信息在理解药物疗效和遗传变异方面的作用.
主要方法:
- 格林受体与阿纳莫雷林和miniGq蛋白的联合结晶.
- 结构分析以确定联体受体相互作用和形状变化.
- 评估由不同的配体诱导的信号偏差,并识别遗传变异.
主要成果:
- 亚纳莫雷林在 ghrelin 受体表现出超激素活性.
- 独特的连接体化学结构诱导独特的受体构造和偏差信号传递.
- 结构洞察力有助于识别影响药物反应的遗传变异.
结论:
- 解明与阿纳莫雷林结合的格林受体的结构,为药物设计提供了一个框架.
- 了解连接体诱导的信号偏差和遗传变异,可以实现个性化的治疗策略.
- 这种方法提高了有效的林受体向药物的选择.
相关概念视频
G Protein-coupled Receptors
11.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.2K
Transducer Mechanism: G Protein–Coupled Receptors
1.8K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.8K
G-protein Coupled Receptors
115.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
115.3K
Regulation of Food Intake
182
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
182
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295


